Focus: Cell Manufacturing & Regulatory T Cell Therapies

During BIO Asia–Taiwan 2025, Taiwan Bio Therapeutics (6892.TWO) announced the signing of a new term sheet with Mayo Clinic, deepening their partnership and officially launching an investment plan in Phoenix, Arizona.

CEO Dr. Cyrus Yang emphasized the joint goal: co-developing proprietary processes to make effective but costly cell therapies more accessible and affordable. The first phase of investment for the Phoenix Innovation Hub is set to begin later this year.

Read more: https://reurl.cc/axnm04

#Globalbio #BIOAsiaTaiwan #TaiMedBiologics #MayoClinic #CellTherapy #Phoenix #BiotechCollaboration